Klin Farmakol Farm. 2010;24(4):178-180

Skin Cancer and Renal Transplantation - University Hospital Olomouc Transplant Center Statistical Analysis Outcomes

Lucie Kalinová1,3, Ondřej Májek2, Daniel Stehlík3, Karel Krejčí4, Petr Bachleda1
1 II. chirurgická klinika, FN Olomouc
2 Institut biostatistiky a analýz, Masarykova univerzita, Brno
3 Oddělení plastické a rekonstrukční chirurgie, FN Olomouc
4 III. interní klinika, FN Olomouc

Aim: To provide the evaluation of skin cancer incidence and to identify factors associated with an increased incidence of skin cancers in

renal transplant recipients followed in the University Hospital Olomouc Transplant Center.

Methods: A retrospective data analysis of medical records of all transplant patients who underwent renal transplantation in the period

1984–2009 and were followed in the University Hospital Olomouc Transplant Center (n = 603). In patients who were reported to have

a diagnosis of cancer date and type of diagnosis were recorded. The cohort was linked with the National Cancer Registry of the Czech

Republic. Patients with a diagnosis of cancer prior to transplantation were excluded from the study. Statistical analysis was performed

using the Mann – Whitney and Chi square test.

Results: In the study population we found cancer de novo after transplantation in 92 patients. Skin cancer had a total of 55 patients.

Fifty-two (94.5 %) patients had non-melanoma skin cancer, 2 (3.6 %) patients had malignant melanoma, and we uncovered one case of

merkel cell carcinoma of the skin. Out of all evaluated parameters, the patient‘s age at the time of transplantation and type of immunosuppressive

therapy showed statistical significance.

Keywords: skin cancer, transplantation, immunosuppression

Published: December 31, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kalinová L, Májek O, Stehlík D, Krejčí K, Bachleda P. Skin Cancer and Renal Transplantation - University Hospital Olomouc Transplant Center Statistical Analysis Outcomes. Klin Farmakol Farm. 2010;24(4):178-180.
Download citation

References

  1. Walder B, Robertson M, Jeremy D. Skin cancer and immunosuppression. Lancet 1971; 2: 1282-1283. Go to original source... Go to PubMed...
  2. Ulrich C, Kanitakis J, Stockfleth E, et al. Skin cancer in organ tranpslant recipient - Where do we stand today? Am J Transpl 2008; 11: 2192-2198. Go to original source... Go to PubMed...
  3. Gupta AK, Cardella CJ, Haberman HF. Cutaneous malignant neoplasms in patients with renal transplants. Arch Dermatol 1986; 122: 1288-1293. Go to original source... Go to PubMed...
  4. Euvrard S, Kanitakis J, Claudy A. Skin cancer after organ transplantation. N Engl J Med 2003; 348: 1681-1691. Go to original source... Go to PubMed...
  5. London NJ, Farmery SM, Will EJ, et al. Risk of neoplasia in renal transplant patients. Lancet 1995; 346: 403. Go to original source... Go to PubMed...
  6. Marcen R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003; 35: 1714-1716. Go to original source... Go to PubMed...
  7. Wisgerhof HC, van der Geest LG, de Fijter JW, et al. Incidence of cancer in kidney-transplant recipients: A long-term cohort study in a single center. Cancer Epidemiol 2010;29 [Epub ahead of print] 7-2010 [cit 20-9-2010] Dostupné na: <http://www.ncbi.nlm.nih.gov/pubmed>. Go to PubMed...
  8. Hiesse C, Rieu P, Kriaa F, et al. Malignancy after renal transplantation: Analysis of incidence and risk factors in 1700 patients followed during a 25-Year period. Transplant Proc 1997; 29: 831-833. Go to original source... Go to PubMed...
  9. Popov Z, Ivanovski O, Kolevski P, et al. De novo malignancies after renal transplantation - a single-center experience in the Balkans. Transplant Proc 2007; 39: 2589-2591. Go to original source... Go to PubMed...
  10. Ju MK, Joo DJ, Kim SJ, et al. Chronologically different incidences of post-transplant malignancies in renal transplant recipients: single center experience. Transpl Int 2009; 22: 644-653. Go to original source... Go to PubMed...
  11. Montagnino G, Lorca E, Tarantino A, et al. Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transplant 1996; 10: 461-469.
  12. Hoshida Y, Tsukuma H, Yasunaga Y, et al. Cancer risk after renal transplantation in Japan. Int J Cancer 1997; 71: 517-520. Go to original source... Go to PubMed...
  13. Bouwes Bavinck JN, Hardie DR, Green A, et al. The risk of skin cancer in transplant patients in Queensland, Australia. Transplantation 1996; 61: 715-721. Go to original source... Go to PubMed...
  14. Cidlowski JA, King KL, Evans-Storms RB, et al. The biochemistry and molecular biology of glucocorticoid-induced apoptosis in the immune system. Recent Prog Horm Res 1996; 51: 457-490; discussion 490-491. Go to PubMed...
  15. Guba M, Graeb C, Jauch KW, et al. Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004; 77: 1777-1782. Go to original source... Go to PubMed...
  16. Blaheta RA, Bogossian H, Beecken WD, et al. Mycophenolate mofetil increases adhesion capacity of tumor cells in vitro.Transplantation 2003; 76: 1735-1741. Go to original source... Go to PubMed...
  17. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on growth factor-beta 1 in invasion and metastasis in gastric carcinoma. J Clin Oncol 1999; 17: 607-614.
  18. Engl T, Relja B, Natsheh I, et al. Modulation of the CXCchemokine expression profile on tumor cells by the immunosuppressive drug mycophenolate mofetil.Int J Mol Med. 2005; 15: 641-647. Go to original source...
  19. Wang K, Zhang H, Li Y, et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 2004; 36: 2068-2070. Go to original source... Go to PubMed...
  20. Salgo R, Gossmann J, Schöfer H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-) malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10: 1385-1393. Go to original source... Go to PubMed...
  21. Opeltz G, Dohler B. Lymphomas after solid organ transplantation: a Collaborative transplant study report. J Am Transplant. 2004; 4: 222-230. Go to original source... Go to PubMed...
  22. Webster AC, Chapman JR. Chapter 10, Cancer. ANZDATA Registry Report 2005. 28th annual report. Adelaide, South Australia: Australia and New Zealand Dialysis and Transplant Registry (http://www.anzdata.org.au); 2006: 131-139.
  23. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4: 905-913. Go to original source... Go to PubMed...
  24. Wei Q, Matanoski GM, Farmer ER. DNA repair and aging in basal cell carcinoma: a molecular epidemiology study. Proc Natl Acad Sci USA 1993; 90: 1614-1618. Go to original source... Go to PubMed...




Clinical Pharmacology and Pharmacy

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.